Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalteparin plus sunitinib in first-line metastatic renal cell carcinoma
NL-OMON39888Phase 1Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2011
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalteparin and sunitinib in renal cell carcinoma (RCC) and kidney cancer, sponsored by Vrije University Medical Center. Primary endpoints: Recommended dosing, Safety and tolerability and 1 more. Started Dec 2011; status: active, not recruiting.
02
Drugs
dalteparinsunitinib
03
Conditions
renal cell carcinoma (RCC)kidney cancer
Beyond the preview
Go deeper on NL-OMON39888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39888.